RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.88%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.12B
AUM Growth
+$1.12B
(+22%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
11.06%
Top 10 Holdings %
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$42.2M |
| 2 |
Medtronic
MDT
|
$9.35M |
| 3 |
Eli Lilly
LLY
|
$8.88M |
| 4 |
Cigna
CI
|
$6.78M |
| 5 |
Cooper Companies
COO
|
$6.74M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$20.3M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$7.48M |
| 3 |
Bristol-Myers Squibb
BMY
|
$5.43M |
| 4 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$4.76M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$4.27M |
Sector Composition
| 1 | Healthcare | 94.2% |
| 2 | Communication Services | 2.08% |
| 3 | Industrials | 0.52% |
| 4 | Technology | 0.02% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $56.6M | 5.04% | 744,354 +554,354 | +292% | +$42.2M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $54M | 4.8% | 695,000 -55,000 | -7% | -$4.27M |
|
3
NovoCure
NVCR
$1.38B
| $45.6M | 4.05% | 409,600 +34,600 | +9% | +$3.85M |
|
4
UnitedHealth
UNH
$281B
| $34.3M | 3.05% | 110,000 +5,000 | +5% | +$1.56M |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $29.9M | 2.66% | 110,000 -27,500 | -20% | -$7.48M |
|
6
Guardant Health
GH
$8.41B
| $26.8M | 2.39% | 240,000 +55,000 | +30% | +$6.15M |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $25.9M | 2.3% | 190,000 +30,000 | +19% | +$4.09M |
|
|
8
Cigna
CI
$80.3B
| $25.4M | 2.26% | 150,000 +40,000 | +36% | +$6.78M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $25.2M | 2.24% | 220,000 +30,000 | +16% | +$3.43M |
|
10
Humana
HUM
$36.5B
| $24.8M | 2.21% | 60,000 +5,000 | +9% | +$2.07M |
|
11
AbbVie
ABBV
$372B
| $24.5M | 2.18% | 280,000 -20,000 | -7% | -$1.75M |
|
|
12
Eli Lilly
LLY
$657B
| $24.4M | 2.17% | 165,000 +60,000 | +57% | +$8.88M |
|
13
Jazz Pharmaceuticals
JAZZ
$7.75B
| $24.2M | 2.16% | 170,000 +32,968 | +24% | +$4.7M |
|
14
Elevance Health
ELV
$71.8B
| $24.2M | 2.15% | 90,000 +25,000 | +38% | +$6.71M |
|
|
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
| $23.5M | 2.09% | 460,000 -10,000 | -2% | -$510K |
|
|
LVGO
16
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $23.4M | 2.08% | 166,961 +41,961 | +34% | +$5.88M |
|
|
17
Medtronic
MDT
$119B
| $22.9M | 2.04% | 220,780 +90,000 | +69% | +$9.35M |
|
18
Abbott
ABT
$231B
| $22.3M | 1.98% | 205,000 +20,000 | +11% | +$2.18M |
|
|
19
Cooper Companies
COO
$13.4B
| $20.2M | 1.8% | 60,000 +20,000 | +50% | +$6.74M |
|
|
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $20.2M | 1.79% | 310,000 +100,000 | +48% | +$6.5M |
|
|
ABMD
21
DELISTED
Abiomed Inc
ABMD
| $19.4M | 1.72% | 70,000 +2,000 | +3% | +$554K |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $19M | 1.69% | 114,311 +14,311 | +14% | +$2.38M |
|
|
IMMU
23
DELISTED
Immunomedics Inc
IMMU
| $18.8M | 1.67% | 221,351 -238,649 | -52% | -$20.3M |
|
24
Gilead Sciences
GILD
$140B
| $18.3M | 1.63% | 290,000 +60,000 | +26% | +$3.79M |
|
25
Centene
CNC
$14.3B
| $17.5M | 1.56% | 300,000 +65,622 | +28% | +$3.83M |
|